Pradžia › Didelis depresinis sutrikimas › Konektikutas
Didelis depresinis sutrikimas klinikiniai tyrimai Konektikutas
16 tyrimai dėl Didelis depresinis sutrikimas ieško dalyvių vietose Konektikutas.
Miestai Konektikutas
Oficialus tyrimo tekstas (anglų kalba)
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- UConn Health Center, Farmington
Renkami dalyviai3 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Connecticut Health Center, Farmington
Renkami dalyviai3 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-25 · NCT05850689A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
Renkami dalyviai3 fazė
Amžius nuo 18 iki 85 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-14 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Institute of Living, Hartford
Renkami dalyviai3 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07076407A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-06 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Ct Clinical Research Associates, Cromwell
Renkami dalyviai3 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Connecticut School of Medicine Psychiatry Department, Farmington
Renkami dalyviai2 fazė
Amžius nuo 18 iki 64 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06547489A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New Haven
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-24 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-24 · NCT06966401The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
Renkami dalyviai2 fazė
Amžius nuo 21 iki 65 · Visoms lytims · Atnaujinta 2026-05-06 · NCT05786066Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Yale University, New Haven
Renkami dalyviai1 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-05-06 · NCT05915013Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Hartford Hospital, Hartford
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 40 · Visoms lytims · Atnaujinta 2026-03-10 · NCT06740383Imaging Depression in Parkinson's Disease
- Yale University, New Haven
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-03-10 · NCT06402955Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #122, Cromwell
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-01-20 · NCT06633016Study of ALTO-300 in MDD
- Site 214, Norwalk
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2025-07-24 · NCT05922878Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.